Spring Bank Pharmaceuticals (SBPH) Issues Earnings Results

Spring Bank Pharmaceuticals (NASDAQ:SBPH) issued its quarterly earnings results on Monday. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.17, Morningstar.com reports.

NASDAQ:SBPH traded up $0.20 during mid-day trading on Tuesday, reaching $10.40. The company’s stock had a trading volume of 1 shares, compared to its average volume of 15,653. The firm has a market cap of $162.86 million, a price-to-earnings ratio of -5.67 and a beta of 0.84. Spring Bank Pharmaceuticals has a twelve month low of $8.14 and a twelve month high of $15.95.

A number of brokerages have issued reports on SBPH. Chardan Capital set a $45.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 30th. Cantor Fitzgerald set a $34.00 price target on Spring Bank Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $33.00.



Several hedge funds and other institutional investors have recently added to or reduced their stakes in SBPH. Renaissance Technologies LLC acquired a new position in shares of Spring Bank Pharmaceuticals in the 2nd quarter valued at about $184,000. Northern Trust Corp lifted its stake in shares of Spring Bank Pharmaceuticals by 103.1% in the 2nd quarter. Northern Trust Corp now owns 37,915 shares of the company’s stock valued at $450,000 after purchasing an additional 19,246 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Spring Bank Pharmaceuticals by 464.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 12,712 shares of the company’s stock valued at $153,000 after purchasing an additional 10,458 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Spring Bank Pharmaceuticals in the 3rd quarter valued at about $122,000. Finally, Jennison Associates LLC acquired a new position in shares of Spring Bank Pharmaceuticals in the 3rd quarter valued at about $8,210,000. 42.87% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Spring Bank Pharmaceuticals (SBPH) Issues Earnings Results” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://dakotafinancialnews.com/2019/03/12/spring-bank-pharmaceuticals-sbph-issues-earnings-results.html.

Spring Bank Pharmaceuticals Company Profile

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).

Featured Story: When is a capital gain realized?

Earnings History for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.